The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignancies were often negative or displayed faint cytolasmic or nuclear staining in a fraction of the cells. One example of low-grade urothelial cancer had strong nuclear positivity and some prostate cancers showed distinct staining of tumor stroma.
Malignant gliomas, liver, pancreatic and renal cancers showed weak to moderate cytoplasmic positivity. Most other malignant cells were negative.
Most malignancies were weakly stained or negative. Several malignant lymphomas, carcinoids and liver cancers showed moderate cytoplasmic staining.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
